MREO
Mereo BioPharma Group plc NASDAQ Listed Apr 24, 2019$0.30
After hrs
$0.31
+0.59%
Mkt Cap $48.5M
52w Low $0.24
2.5% of range
52w High $2.94
50d MA $0.30
200d MA $0.98
P/E (TTM)
-1.4x
EV/EBITDA
—
P/B
1.2x
Debt/Equity
0.0x
ROE
-102.4%
P/FCF
-1.6x
RSI (14)
36.70
ATR (14)
$0.03
Beta
0.38
50d MA
$0.30
200d MA
$0.98
Avg Volume
5.3M
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
One Cavendish Place · London W1G 0QF · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.01 | -0.01 | +0.0% | 0.36 | -3.5% | -5.2% | +0.2% | -1.9% | +4.1% | -3.1% | — |
| Nov 10, 2025 | AMC | -0.01 | -0.01 | -20.4% | 1.77 | +1.1% | +5.6% | -1.6% | -3.3% | +0.0% | -0.6% | — |
| Aug 12, 2025 | AMC | -0.01 | -0.02 | -100.0% | 1.66 | +0.0% | +4.2% | -1.2% | +1.8% | -3.4% | -2.4% | — |
| May 13, 2025 | AMC | -0.01 | -0.02 | -100.0% | 2.32 | +0.9% | -0.4% | -5.6% | +2.8% | +2.2% | +0.4% | — |
| Mar 26, 2025 | AMC | -0.02 | -0.01 | +50.0% | 2.37 | +13.9% | +1.7% | -4.6% | -2.2% | -3.6% | +9.2% | — |
| Nov 12, 2024 | AMC | -1.36 | -7.69 | -465.4% | 4.10 | -1.5% | -1.2% | -5.7% | -7.6% | -5.7% | +4.8% | — |
| Aug 13, 2024 | AMC | -0.78 | -0.02 | +97.4% | 3.76 | +0.0% | +5.1% | +3.3% | +6.1% | +3.2% | -0.7% | — |
| May 15, 2024 | AMC | — | -0.01 | — | 3.17 | -0.6% | +3.2% | -2.1% | +1.9% | -6.7% | -1.6% | — |
| Mar 27, 2024 | AMC | -0.02 | -0.01 | +44.5% | 3.00 | +3.3% | +10.0% | +3.3% | -0.9% | +0.9% | -4.4% | — |
| Nov 17, 2023 | AMC | — | -0.01 | — | 2.08 | +1.0% | +5.3% | +4.1% | -8.6% | +3.1% | -8.4% | — |
| Sep 7, 2023 | AMC | -0.02 | -0.03 | -37.0% | 1.43 | -0.7% | -1.4% | -2.1% | +1.4% | +2.9% | +11.1% | — |
| Jun 27, 2023 | AMC | — | -0.01 | — | 1.20 | +0.0% | +5.8% | +0.0% | +3.9% | -2.3% | -0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 | JP Morgan | Downgrade | Overweight → Neutral | — | $0.34 | $0.33 | -3.5% | +0.2% | -1.9% | +4.1% | -3.1% | -2.9% |
| Jan 16 | BTIG | Maintains | Buy → Buy | — | $0.67 | $0.71 | +5.9% | -4.5% | -11.7% | -6.2% | +0.4% | -1.0% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $0.57 | $0.55 | -3.7% | +16.3% | +8.6% | -6.4% | -4.5% | -11.7% |
| Dec 30 | Jefferies | Downgrade | Buy → Hold | — | $0.29 | $0.30 | +5.5% | +29.8% | +12.5% | +22.5% | -5.8% | -21.1% |
| Dec 29 | BTIG | Maintains | Buy → Buy | — | $2.31 | $0.25 | -89.2% | -87.6% | +29.8% | +12.5% | +22.5% | -5.8% |
| Dec 29 | LifeSci Capital | Downgrade | Outperform → Market Perform | — | $2.31 | $0.25 | -89.2% | -87.6% | +29.8% | +12.5% | +22.5% | -5.8% |
| Dec 22 | Needham | Maintains | Buy → Buy | — | $2.00 | $2.09 | +4.5% | +14.5% | +0.0% | +0.4% | +0.4% | -87.6% |
| Dec 18 | BTIG | Maintains | Buy → Buy | — | $1.92 | $1.94 | +1.0% | +0.0% | +4.2% | +14.5% | +0.0% | +0.4% |
| Aug 25 | JP Morgan | Maintains | Overweight → Overweight | — | $1.70 | $1.74 | +2.4% | +2.4% | +1.1% | +0.0% | -0.6% | -2.3% |
| Jul 10 | Needham | Maintains | Buy → Buy | — | $2.94 | $2.03 | -31.0% | -42.5% | -4.7% | +6.8% | -0.6% | +2.3% |
| May 13 | Needham | Maintains | Buy → Buy | — | $2.50 | $2.50 | +0.0% | -7.2% | -0.4% | -5.6% | +2.8% | +2.2% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $1.76 | $1.70 | -3.4% | +8.0% | -3.7% | +6.6% | -2.6% | +5.3% |
| Mar 26 | Needham | Maintains | Buy → Buy | — | $2.35 | $2.35 | +0.0% | +0.9% | +1.7% | -4.6% | -2.2% | -3.6% |
| Mar 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.63 | $2.61 | -0.8% | -3.8% | +2.0% | -0.8% | -7.0% | +4.6% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $3.55 | $3.30 | -7.0% | -5.9% | -8.4% | -1.0% | -4.3% | -1.4% |
| Dec 17 | Needham | Maintains | Buy → Buy | — | $3.45 | $3.40 | -1.4% | -1.4% | -2.6% | -0.6% | +1.8% | +1.2% |
| Nov 12 | Needham | Maintains | Buy → Buy | — | $4.28 | $4.16 | -2.8% | -4.2% | -1.2% | -5.7% | -7.6% | -5.7% |
| Oct 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.11 | $4.15 | +1.0% | +1.5% | +2.9% | +2.6% | +0.0% | -3.4% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.28 | $4.26 | -0.5% | +5.1% | -12.2% | +6.8% | +1.4% | -0.7% |
| Aug 13 | Needham | Maintains | Buy → Buy | — | $3.72 | $3.73 | +0.3% | +1.1% | +5.1% | +3.3% | +6.1% | +3.2% |
| Jul 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.88 | $3.86 | -0.5% | +2.6% | +3.8% | -4.4% | +3.3% | +2.0% |
| Jun 20 | Leerink Partners | Maintains | Outperform → Outperform | — | $3.98 | $4.02 | +1.0% | -2.3% | +2.3% | -5.5% | -6.9% | -0.3% |
| Jun 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.52 | $3.94 | +11.9% | +8.8% | +4.2% | +6.5% | +0.0% | -6.4% |
| Jun 12 | Needham | Maintains | Buy → Buy | — | $3.52 | $3.94 | +11.9% | +8.8% | +4.2% | +6.5% | +0.0% | -6.4% |
| May 16 | Needham | Maintains | Buy → Buy | — | $3.17 | $3.15 | -0.6% | +3.2% | -2.1% | +1.9% | -6.7% | -1.6% |
| May 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.17 | $3.15 | -0.6% | +3.2% | -2.1% | +1.9% | -6.7% | -1.6% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $3.13 | $3.03 | -3.2% | -6.1% | -6.8% | -0.7% | -1.8% | +0.7% |
| Mar 28 | Needham | Maintains | Buy → Buy | — | $3.00 | $3.10 | +3.3% | +10.0% | +3.3% | -0.9% | +0.9% | -4.4% |
| Mar 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.00 | $3.10 | +3.3% | +10.0% | +3.3% | -0.9% | +0.9% | -4.4% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.96 | $3.00 | +1.4% | +0.7% | -0.3% | -0.7% | +1.7% | +10.0% |
| Sep 8 | Needham | Maintains | Buy → Buy | — | $1.43 | $1.42 | -0.7% | -1.4% | -2.1% | +1.4% | +2.9% | +11.1% |
| Sep 8 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.43 | $1.42 | -0.7% | -1.4% | -2.1% | +1.4% | +2.9% | +11.1% |
| Aug 23 | Needham | Maintains | Buy → Buy | — | $1.24 | $1.35 | +8.9% | +12.9% | +0.0% | +14.3% | +4.4% | -12.6% |
| Jun 6 | Needham | Maintains | Buy → Buy | — | $1.05 | $1.15 | +9.5% | +9.5% | +7.8% | +8.9% | -1.5% | -6.0% |
| May 26 | Needham | Maintains | Buy → Buy | — | $1.06 | $1.08 | +1.9% | +0.9% | -9.1% | +3.9% | +0.0% | +5.0% |
| Apr 21 | Needham | Maintains | Buy → Buy | — | $1.05 | $1.08 | +2.9% | -5.7% | +5.1% | +7.7% | +9.8% | -2.4% |
| Mar 30 | Needham | Maintains | Buy → Buy | — | $0.74 | $0.73 | -1.4% | -4.0% | -0.5% | +11.3% | +1.2% | +4.3% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $0.77 | $0.79 | +2.9% | +1.5% | +4.0% | -7.8% | +5.9% | -4.3% |
| Aug 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.15 | $1.23 | +7.0% | +17.4% | -3.7% | -7.7% | -1.7% | -0.8% |
| Jun 6 | Needham | Maintains | Buy → Buy | — | $0.57 | $0.57 | +0.0% | -2.8% | +12.8% | +2.4% | +7.8% | -4.8% |
| May 5 | BTIG | Maintains | Buy → Buy | — | $3.49 | $3.66 | +4.9% | -1.1% | -4.3% | +2.1% | -7.4% | +4.8% |
| Apr 5 | Needham | Maintains | Buy → Buy | — | $3.38 | $3.68 | +8.9% | +10.9% | +3.2% | +3.1% | +1.0% | +1.2% |
No insider trades available.
8-K
Mereo BioPharma Group plc -- 8-K Filing
May 14
8-K · 2.02
!! High
Mereo BioPharma Group plc -- 8-K 2.02: Earnings Results
May 12
8-K
Mereo BioPharma Group plc -- 8-K Filing
Mereo BioPharma (MREO) faces delisting risk from Nasdaq Capital Market due to failing the bid price requirement, with a compliance period to cure the deficiency or risk removal from the exchange.
Feb 17
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bank Of America Corp /de/ | 8,195,287 | $3M | Added | Mar 2026 |
| 2 | Defilade Capital Management, L.p. | 7,558,756 | $2M | New | Mar 2026 |
| 3 | Millennium Management | 3,559,103 | $1M | Added | Mar 2026 |
| 4 | Morgan Stanley | 2,547,570 | $1M | Reduced | Dec 2025 |
| 5 | Tejara Capital Ltd | 2,037,520 | $672K | Reduced | Mar 2026 |
| 6 | Monaco Asset Management Sam | 1,585,214 | $661K | Added | Dec 2025 |
| 7 | Ubs Group Ag | 1,490,128 | $492K | Reduced | Mar 2026 |
| 8 | Wealthspire Advisors, Llc | 796,036 | $263K | New | Mar 2026 |
| 9 | Marshall Wace, Llp | 686,987 | $227K | New | Mar 2026 |
| 10 | Jane Street Group, Llc | 356,004 | $148K | Reduced | Dec 2025 |
| 11 | Rangeley Capital, Llc | 329,200 | $109K | Reduced | Mar 2026 |
| 12 | Knott David M Jr | 300,337 | $99K | — | Mar 2026 |
| 13 | Citigroup Inc | 195,814 | $82K | New | Dec 2025 |
| 14 | Acadian Asset Management Llc | 209,084 | $68K | Added | Mar 2026 |
| 15 | Susquehanna International Group, Llp | 195,920 | $65K | New | Mar 2026 |
| 16 | Two Sigma Investments, Lp | 187,839 | $62K | Reduced | Mar 2026 |
| 17 | Adar1 Capital Management, Llc | 150,000 | $50K | New | Mar 2026 |
| 18 | Virtus Investment Advisers, Llc | 125,662 | $41K | Added | Mar 2026 |
| 19 | Caption Management, Llc | 50,000 | $21K | Reduced | Dec 2025 |
| 20 | Renaissance Technologies Llc | 48,400 | $16K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF | 213,432 | $94K | Jan 2026 |
| 2 | Virtus LifeSci Biotech Clinical Trials ETF | 129,828 | $57K | Jan 2026 |
| 3 | Fidelity Nasdaq Composite Index Fund | 92,534 | $34K | Feb 2026 |
Valuation
Market Cap
$48.5M
Enterprise Value
$7.5M
P/E (TTM)
-1.36x
Forward P/E
—
PEG Ratio
0.14x
P/B
1.19x
P/S
96.99x
P/FCF
-1.56x
EV/EBITDA
—
Shares Out
159.4M
Financials (TTM)
Revenue
$500K
Net Income
-$35.7M
EBITDA
-$39.3M
Free Cash Flow
-$31.0M
Op Cash Flow
-$31.0M
EPS Basic
$-0.26
EPS Diluted
$-0.22
EPS Forward
$-0.01
Gross Margin
-105.7%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$45.9M
Total Liab.
$5.0M
Total Equity
$40.9M
Cash
$41.0M
LT Debt
$0
Book Value/Sh
$0.26
Debt/Equity
0.00x
Current Ratio
10.46
Quick Ratio
10.46
Returns & Growth
ROE
-102.4%
ROA
-91.2%
ROIC
-96.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
+11.1%
Price Returns
2W
+39.8%
1M
+28.2%
3M
-7.2%
6M
-81.6%
12M
-84.0%
Technicals
52W High
$2.94
52W Low
$0.24
50d MA
$0.30
200d MA
$0.98
RSI (14)
36.70
ATR (14)
$0.03
Beta
0.38
Avg Volume
5.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$0.83
High
$1.00
Low
$0.50
Median
$1.00
Data updated apr 26, 2026 1:13pm
· Source: financialmodelingprep.com